secwatch / observer
8-K filed January 11, 2023, 6:59 PM ET ticker AVNS CIK 0001606498
other material confidence high sentiment neutral materiality 0.75

AVANOS MEDICAL, INC. (AVNS): restructuring charge — Avanos launches 3-year transformation; CFO Greiner adds Chief Transformation Officer role; SVP Haydon to depart

AVANOS MEDICAL, INC.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

William D. Haydon

Senior Vice President and General Manager, Pain Franchise
AVNS · AVANOS MEDICAL, INC.
Effective
2023-03-31
Filed
January 11, 2023, 6:59 PM ET
On January 10, 2023, the Company and William D. Haydon, the Company’s Senior Vice President and General Manager, Pain Franchise, entered into a Severance and Separation Agreement (the “Severance and Separation Agreement”) pursuant to which: (i) Mr. Haydon’s employment with the Company will terminate effective March 31, 2023 (the “Separation Date”);

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

William D. Haydon was terminated as Senior Vice President and General Manager, Pain Franchise at AVANOS MEDICAL, INC..

Action
terminated
Role
Senior Vice President and General Manager, Pain Franchise
Exact text from the filing
On January 10, 2023, the Company and William D. Haydon, the Company’s Senior Vice President and General Manager, Pain Franchise, entered into a Severance and Separation Agreement (the “Severance and Separation Agreement”) pursuant to which: (i) Mr. Haydon’s employment with the Company will terminate effective March 31, 2023 (the “Separation Date”);
View on SEC.gov
Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.7

AVANOS MEDICAL, INC. announced a restructuring affecting Chronic Care and Pain franchises combined into single commercial organization; exit certain low-margin, low-growth product categories.

Type
restructuring
Affected area
Chronic Care and Pain franchises combined into single commercial organization; exit certain low-margin, low-growth product categories
Exact text from the filing
On January 10, 2023, Avanos Medical, Inc. (the “Company”) approved a three-year transformation process (the “Transformation Process”) pursuant to which the Company plans to: (i) combine its Chronic Care and Pain franchises into a single commercial organization focused on the Digestive Health and Orthopedic Pain & Recovery product categories; (ii) exit certain low-margin, low-growth product categories, including through targeted divestitures; (iii) undertake additional cost management activities to enhance the Company’s operating profitability; and (iv) pursue efficient capital allocation strategies, including through acquisitions that meet the Company’s strategic and financial criteria.
View on SEC.gov

Browse all restructurings & charges →

AVANOS MEDICAL, INC. filing history →

Source: SEC EDGAR
accession 0001606498-23-000011
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.